Home » Janssen Pharmaceutics
Category Archives: Janssen Pharmaceutics
In the newspaper of the 26 of March, I read that drugs are going to become cheaper. The government is trying to make 2,500 drugs of all kinds cheaper (chronical treatments such as diabetes but also antibiotics and the contraceptive pill), as the minister of Public Health Laurette Onkelinx (PS).says. For some drugs the price reduction can be 50, 60 or even 70%, but she indicates that it is the only way to make drugs available for everybody. Last year, a reduction of the 1.95% was required to fit the budget agreement. Later on an even harder reduction was necessary by the obligated comparison within six European countries. as expected, the pharmaceutical sector was not really pleased with this fact, and the negotiations did not go easily. This is a strong sector, and it provides about 31,000 people with work. For this reason, a consensus had to be found: the prices are going to be reduced and the companies get support in their research. Since the first of April, the new prices are legit, and a saving of ten million Euros should be accomplished.
I think this is a lice initiative, but the problem is only shoved around instead of taken care of. The pharmaceutical sector is trying to innovate and make better drugs, improve existing drugs and invent new ones. As there are still a lot of diseases that cannot be cured, or resistant variants of the disease are developed, the pharmaceutical sector will always need to be able to respond to this. A second remark, is the fact that, once a drug is developed, it is only patented for a certain period. After this period other companies can make the drug as well, and use it as a base for new drug development, or homeopathic variants of the drugs can be made. These all have a great impact on the pharmaceutical sector. As I already said in a previous post, the employees of Janssen are afraid of losing their job, since the division of Springhouse had closed its R&D site. This is another slap in the face for these employees. If they lose their job, the lower prices of drugs will not concern them that much, and an even harder decrease will be necessary as the unemployment will increase.
In the R&D, it is not unusual to work with external partners. It is thanks to innovation that it is possible to share ideas, have opinions and be able to change your original vision. This is made possible by the establishment of C.R.E.A.T.e or ‘Community of Research Excellence & Advanced Technology’ that has taken an important step towards the extension of an innovative discovery organization on world scale. In the past, every research team and every pharmaceutical actor, behaved like it was on an island, where the results never left. By the use of an open innovative environment, everything is possible these days.
CREATe plays the role of partner and integrator within Janssen. By working international together with about 350 people, equally divided in Europe and the US, it is possible to share ideas with the world. The assignment of CREATe is to identify and help the movement of compounds in the early stages of development in order to increase the chance of a positive outcome. Within Europe, I am proud to pronounce, that Beerse is the largest team, next to Val de Reuil (France) and Toledo (Spain). Both Europe and the US have experts that the other teams need, and this is why it is important to communicate in an open way.
CREATe has four strategic areas namely: core scientific technologies, molecular sciences, integrative system Biology and translational sciences. The first area, core scientific technologies, registers every molecule that has ever been synthesized within Janssen. It is the goal of CREATe to further complement this library. The second area of molecular sciences tries to make it easier to find the right couple the right target substances to the corresponding diseases. Integrative system Biology is the third area, where tests are developed in order the research the effects of a molecule. The fourth and last area is translational sciences. Here the capacity is tested, with which a molecule will be accepted by the body and the improvement of the safety of a chemical molecule.
These four areas are important to secure a safe future for the patients, and new ideas are getting harder to come up with. Do you think you can come up with some possibilities for future drugs or improvements?
The hard times of today me never make us forget about the future. Durability is a very important goal for that matter. This is why Janssen Pharmaceutics created the Sustainability Council that is committed to promote a sustainability entrepreneurship. Every project has three different parts: an environmental part, a social part and, of course, an economic part. Not only does every project aims for these three goals, it aims to get in every division. In order to do so, every division is represented by a responsible, such as the IT-group, which can help to get the initiatives to the right persons. For already a long time, Janssen has been in the possession of solar panels and windmills, but a lot of people just do not know it. Another example is the reuse of the rinse water from the washing department, even up to three times! The large amount of plastic cups are even more durable than the reusable coffee mugs that have to be washed every time.
As a plan of action, the first step is to list everything that is already taken into account, such as the solar panels, windmills, recycling of rinsing water and the use of plastic cups. Secondly, these actions need to be clarified to the employees, and this is where we are now. The three musketeers are present in every alley and make the employees of Janssen aware of what is going on, and what they can do to help. It is important to know that every little step counts, and you have to begin with yourself. Only by taking responsibility for the present and future generations, will Janssen be able to maintain the strong role it is laying now.
To limit the ecological footprint, the use of water, energy and other raw materials need to be monitored. An important difficulty is that purification of water and waste treatment costs a lot of energy and money. So by limiting the amount of waste and water, it is not only advantageous for the environment, but it is also cheaper for the company and it decreases the health risks of the employees because they do not have to use dangerous solvents or diluents. Next to this economic part, the social part is very important as well. This is linked because by making profit, it is possible to make new drugs, new developments and get the drugs to the patients on time.
This is a post as a reaction to what has been on the news concerning the drug ‘Motilium’. The EMA (European Medicine Agency) has started an investigation to the drugs that consist of domperidone as an active substance. The most well-known drugs is Motilium, which is used to treat nausea, vomiting, a bloating feeling and an upset stomach. These drugs might have a connection to heart diseases, and the FAGG (‘Belgisch Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten’) or FAMHP (Federal Agency for Medicines and Health Products) has asked for this investigation.
A “Product Issue Management Team” has been established with the goal to work close with the European authorities to help the ongoing research as efficiently and minimal disturbance for patients, clients and healthcare professionals as possible. This makes it possible to maintain the daily affairs of Janssen EMEA. This team strives to have no secrets, and will communicate on time and consistent to all who need the information. Important to know, is that this intervention will take a few months, and if you take your drugs as prescribed in the information leaflet.
Johnson & Johnson Consumer NV, a division of the same group of American companies that also include Janssen Pharmaceutics, still has faith in a positive benefit-risk ratio of the drug, and fully supports the European and Belgian producers of the drugs and will fully cooperate with the investigation.
Johnson and Johnson (J&J) are aware of the problems concerning domperidone, and are already following this for several years and will be passed to the regulators. Since 2011, they are performing two studies in collaboration with the FAMHP. One of these studies was concerning a cardiovascular safety study, which has been completed and that will be published this year. The company has already announced that the results where reassuring. The second study is investigating the link between domperidone and the cardiovascular effects and will be finished at the end of this year. A last remark is that J&J want to make sure that drugs containing domperidone will have to require prescription. If this will be the case will be announced at the end of April.
Although this is a period of crisis and sometimes even devices get sabotaged by people who got fired, Janssen Pharmaceutics is still committed for development Cooperation’s where they want to help the population. A perfect example is ‘Move for Africa’ by La Libre Belgique, because they have the same vision as Janssen Pharmaceutics: making a durable and tangible difference for the world. Move for Africa is a Walloon organization that stands for awareness campaigns and this with the support of the Walloon Minister of Education. They try to promotion the development cooperation and humanitarian aid to Africa, especially to the students of the 5th grade of the secondary schools in Wallonia. During this Easter holydays, about hundreds to hundred and fifty students, or ten classes, will elaborate concrete development projects in different African countries. They will collect money, which will fully go to these projects.
Doing this, makes young people aware that there are different aspects to development Cooperation’s. Janssen Pharmaceutis is one of the project promoters and partners, which want to learn the students, what their responsibility is as a citizen of the world, thereby stimulating them to cooperate to the development of a democratic society.
Janssen feels responsible for and involved in the future of the youth, thus it wants to sensitize them in order to make fully committed to work for a better world, the future of our children. Secondly, they want to make them enthusiast for a scientific career, since they are the generation that have to answer the challenges of today and tomorrow. Therefore it is highly appreciated when a student invests its time, talent and energy in a sustainable world and accordingly in projects such as Move for Africa.
For more information, be sure to visit the website of Move for Africa: http://moveforafrica.lalibre.be/
In the field of research and development (R&D) a lot of investments are necessary. As explained in the blog of ‘maintenance’, saving are done as much as possible. For my thesis I test whether the XBridge column (± 6000€) can replace the SunFire column (± 5000€). This is a difference of approximately 1000€ but the lifetime of this column is higher. How long will be tested by recording how many times the column is used until the column no longer provides good separations. Although a present investment of 1000€ in this column can eventually lead to savings over a certain period. In order to get the opportunity to test something, everything needs to be requested in advance, motivated why it could be necessary and tested for its usefulness. This is what I am testing at the moment. Firstly the tests are done on a small scale, namely analytical separations, wherefrom the translation can be done to the larger scale or preparative separations.
Another advantage of the XBridge, is the availability of an XBridge XP column which can result in a shorter time of analysis. This means that more purifications can be done. But we bumped into the limiting factor of solubility. The column was not able to reach the necessary flow rate and overpressure made the HPLC to go in shut down. The first choice was to ask for a Ultra high Pressure (Performance) Chromatography or UPLC device, but this application was rejected. Thus another solution needed to be made and this was changing the methods and discussing this problem with the manufacturer of the column, a reduction of five minutes can be made so far. This might not seem much, but five minutes per test can be a great difference if you know that about ten to twenty tests are done every day. Testing this further, based on trial and error, there is a possibility for an even greater reduction in time.
A small announcement for those of interest. On Sunday the 17 of March it is the international day of care. During this day, Janssen will organize an open house at which everyone is welcome from 10 to 15 in Beese Turnhoutseweg 30.
Reorganization is a common way for companies to save money and prevent bankruptcy. Since the year 2001, Janssen Pharmaceutics is forced to reorganize, and it still going on now. As a cause of this, a lot of people lost their jobs, especially in the US. This is because employees are not as well protected as the unions protect the workers here in Belgium. When the reorganization reaches Belgium, the fired workers are let go over a certain period of time. The last victims of the reorganizations of 2001 unemployed since 2004. Sonja Willems, the managing Director of Janssen Pharmaceutics, managed to save more than half of the jobs when a great amount of people was fired during this period. First of all, there was a period in which employees could voluntary leave the company. As a compensation, they got a bonus. Afterwards, the people who were about to retire got their early retirement, and lastly some compulsory redundancies were made. These people were guided in their search of a new job and some of them found a new job within Janssen Pharmaceutics.
A more recent example is the closure of the division Springhouse in the US, that has been close entirely from one day to the next. To reduce panic, an emergency meeting was set up, but nothing could be clarified. Now, the staff of research and development (R&D) are afraid to lose their job as well. This is since the director cannot guarantee that the reorganization will not happen in Beerse, and in the past it has always been the R&D who got the hardest hit. a possible explanation is that the Board of Directors wants to evolve with the market and be innovative. In order to make this possible, a lot of new ideas and new ways of working are necessary. The R&D is very fragile in this way of thinking, due to the fact that this is the core where renewal is being explored and tested.
All this commotion results in stress on the work floor, and some are already looking for a different job. Some people, such as the security guards and cleaning services, are being replaced by external companies. These peoples contract is not as binding as the people working for Janssen directly. Thus when these people need to be fired, it is much easier and Janssen does not have any obligations towards these people. Another advantage is that this is much cheaper for Janssen as well.
All this is still the result of the crisis, but what can we do about it? How can we make sure we have certainty in the future? What can we do to make it better for our children?